Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia

Thrombosis and Haemostasis

Volumn 106, Issue 4, 2011, Pages 641-645

  Ragni, Margaret V ^a,b   Jankowitz, Rachel C ^a   Jaworski, Kristen ^b   Merricks, Elizabeth P ^c   Kloos, Mark T ^c   Nichols, Timothy C ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Hemophilia Center of Western Pennsylvania   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trial; Interleukin 11; Menorrhagia; Von willebrand disease; Women

Indexed keywords

MESSENGER RNA; RECOMBINANT INTERLEUKIN 11; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONJUNCTIVA DISEASE; CONJUNCTIVA ERYTHEMA; DIASTOLIC HYPERTENSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUID RETENTION; FLUSHING; HUMAN; HYPERTENSION; HYPOKALEMIA; INJECTION SITE CONTUSION; MENORRHAGIA; MENSTRUAL CYCLE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PICTORIAL BLOOD ASSESSMENT CHART; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIDE EFFECT; THROMBOCYTOSIS; TREATMENT DURATION; TREATMENT OUTCOME; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; BLOOD PLATELETS; DISEASE PROGRESSION; DRUG RESISTANCE; ERYTHEMA; FEMALE; HUMANS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-11; MENORRHAGIA; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR; WOMEN'S HEALTH;

EID: 80053180612     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-04-0274     Document Type: Article

References (27)

1. Ragni MV, Bontempo FA, Cortese-Hassett AL. Von Willebrand disease and bleeding in women. Haemophilia 1999; 5: 313-317.
2. James A, Ragni MV, Picozzi V. ASH Special Educational Symposium: Bleeding Disorders in Premenopausal Women: Another Public Health Crisis for Hematology. Hematology 2006; 474-485.
3. Kouides PA, Kadir RA. Menorrhagia associated with laboratory abnormalities of hemostasis: epidemiological, diagnostic, and therapeutic aspects. J Thromb Haemost 2007; 5 (Suppl 1): 175-182.
4. Kadir RA, Chi C. Women and von Willebrand Disease: Controversies in diagnosis and management. Sem Thromb Haemost 2006; 32: 605-615.
5. Kadir RA, Edlund M, von Mackensen S. The impact of menstrual disorders on quality of life in women with inherited bleeding disorders. Haemophilia 2010; 16: 832-839.
6. Mannucci PM. Desmopressin in the treatment of bleeding disorders: the first 20 years.Blood 1997; 90: 2515-2521.
7. Rodeghiero F, Castaman G, Tosetto A et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international multicenter study. J Thromb Haemost 2005; 3: 2619-2626.
8. Kadir RA, Lee CA, Sabin CA, et al. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia 2002; 8: 787-793.
9. Byams VR, Baker J, Brown DL, et al. Baseline characteristics of females with bleeding disorders receiving care in the U.S. HTC Network. National Conf on Blood Disorders in Public Health 2010; 77: E3. Abstract 4.
10. Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009; 145: 212-220.
11. Nichols WL, Hultin MB, James AH, et al. Von Willebrand Disease (VWD): Evidence-based diagnosis and management guidelines, the National Heart Lung and Blood Institute (NHLBI) Expert Panel Report (USA). Haemophilia 2008; 14: 171-232.
12. Medical Product Safety. In Healthy People 2010: A Systematic Approach to Health Improvement. 2003; 17: 3-19.
13. Tepler I, Elias L, Smith JW, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87: 3607-3614.
14. Gordon M, Kaye JA, McCaskill-Steffens WJ, et al. A phase I trial of recombinant human interleukin-11 (Neumega, rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996; 87: 3615-3624.
15. Ragni MV, Jankowitz RC, Chapman HL, et al. A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease. Haemophilia 2008; 14: 968-977.
16. Janssen CAH, Scholten PC, Heintz APM. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995; 85: 977-982.
17. Haberichter SL, Merricks EP, Fahs SA, et al. Reestablishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells. Blood 2005; 105: 145-152.
18. Benson RE, Catalfamo JL, Dodds WJ. A multispecies enzyme-linked immunosorbent assay for von Willebrand factor. J Lab Clin Med 1992; 119: 420-427.
19. Brouland JP, Egan T, Roussi J, et al. In vivo regulation of von Willebrand factor synthesis: von Willebrand factor production in endothelial cells after lung transplantation between normal pigs and von Willebrand factor-deficient pigs. Arterioscler Thromb Vasc Biol 1999; 19: 3055-3062.
20. Nichols TC, Bellinger DA, Reddick RL, et al. The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia A. Blood 1993; 81: 2644-2651.
21. Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood 2003; 102: 442-448.
22. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, June 14, 2010; Available at: http://ctep.cancer.gov/forms/CTCAEv4.pdf.
23. Kyrtle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-462.
24. Edlund M, Blomback M, He S. On the correlation between local fibrinlytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin. Blood Coag Fibriniolysis 2003; 14: 593-598.
25. Luxembourg B, Schmitt J, Humpich M, et al. Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: a focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP). Thromb Haemost 2009; 102: 668-675.
26. Bach J, Haubelt H, Hellstern P. Sources of variation in factor VIII, von Willebrand factor and fibrinogen measurements. Thromb Res 2010; 126: e188-195.
27. Ragni MV, Kessler CM. Hemophilia and Von Willebrand Disease Subcommittee: Four Randomized Controlled Clinical Trial Concepts. State of the Science Symposium in Transfusion Medicine, Hemostasis and Thrombosis (SoS-TMH), NHLBI, Bethesda MD, September 14, 2009.